Ensysce Biosciences (ENSCW) Asset Utilization Ratio (2021 - 2025)
Ensysce Biosciences (ENSCW) reported Asset Utilization Ratio of 1.03 for Q3 2025, up 41.24% year-over-year from 0.73 in Q3 2024, and down 29.56% quarter-over-quarter from 1.46 in Q2 2025.
Ensysce Biosciences (ENSCW) Asset Utilization Ratio (2021 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 5 years of Asset Utilization Ratio data on file, last reported at 1.03 in Q3 2025.
- Asset Utilization Ratio for Q3 2025 came in at 1.03, up 41.24% year-over-year; the trailing twelve-month figure through Sep 2025 was 1.03 (up 41.24% YoY), and the FY2024 annual result was 1.25, up 141.67% from the prior year.
- Asset Utilization Ratio slipped to 1.03 in Q3 2025 per ENSCW's latest filing, from 1.46 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 1.46 in Q2 2025 and troughed at 0.17 in Q2 2021.
- A 5-year average of 0.58 and a median of 0.5 in 2021 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2025: Asset Utilization Ratio tumbled 45.82% in 2022, then surged 298.33% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.27 in 2021, then surged by 31.75% to 0.36 in 2022, then soared by 111.41% to 0.75 in 2023, then dropped by 7.6% to 0.7 in 2024, then soared by 47.43% to 1.03 in 2025.
- Business Quant data shows ENSCW's Asset Utilization Ratio at 1.03 in Q3 2025, 1.46 in Q2 2025, and 1.22 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.03 |
| Jun 30, 2025 | 1.46 |
| Mar 31, 2025 | 1.22 |
| Dec 31, 2024 | 0.70 |
| Sep 30, 2024 | 0.73 |
| Jun 30, 2024 | 0.37 |
| Mar 31, 2024 | 0.45 |
| Dec 31, 2023 | 0.75 |
| Sep 30, 2023 | 0.66 |
| Jun 30, 2023 | 0.58 |
| Mar 31, 2023 | 0.55 |
| Dec 31, 2022 | 0.36 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | 0.36 |
| Mar 31, 2022 | 0.27 |
| Dec 31, 2021 | 0.27 |
| Sep 30, 2021 | 0.24 |
| Jun 30, 2021 | 0.17 |
| Mar 31, 2021 | 0.50 |